Please note that the discussion on today's call includes certain non-GAAP financial measures, including adjusted EBITDA and adjusted net income. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP metric is available in our earnings release. We had a strong start to the year with earnings growth and margin expansion, despite total revenue being essentially flat, underscoring the resilience of the business. We grew adjusted net income by 22% year over year, expanded corporate gross margins to 71%, and generated approximately $58 million of operating cash flow during the quarter.
We believe the first quarter results likely represent the trough revenue baseline from which we would expect to be able to drive growth in the coming quarters. Key drivers of that, in our view, will be enduring ASCENIV demand, expanding margins, and continued strong cash generation. ASCENIV end market demand reached record levels in the first quarter, with revenue growth of approximately 28% year over year. We saw continued strength in record metrics across new patient starts, prescriber adoption, product pull-through, and patient adherence.
Importantly, with a balanced mix of internal and third-party plasma procurement, we believe we have ample supply of high-titer plasma to support both our near- and long-term ASCENIV growth objectives. Our balance sheet remains strong, with pro forma net leverage below 0.5 times, driven by continued cash generation and adjusted EBITDA growth. Which should provide us with the flexibility needed to support growth and activate on our capital allocation priorities. We believe that historically, the plasma fractionation industry has been in a dislocated state where IG utilization demand has outpaced the industry's ability to supply.